Recent retrospective studies have suggested that the anaesthetic technique during cancer surgery may influence the progression of the underlying malignant disease. 1 -3 The immune-modulatory effects of opioids or other anaesthetic agents, 4 neuraxial blocks, and stress response of surgery may all have a part to explain this association. 5 Nuclear medicine techniques have shown that peripheral lymphatics are under autonomic control in much the same way as blood vessels that supply the same anatomic region. 6 Lymph-veins, formed by the joining of lymphatic capillaries, have contractile smooth muscles and the segment of the vessel between successive valves is called a lymphangion. The lymphangion contracts when it is filled with lymph and when there is sympathetic stimulation. 7 Rabbit ear chamber studies have
shown that there is active recruitment of regional lymphatics and clearance of perilymphatic cell debris after mechanical tissue injury. 8 Similarly, surgical trauma may contribute to an increased lymph flow as suggested in a lymphoscintigraphic study of patients with lymphoedema of the lower extremity. 9 As such, it is possible that the spread of disrupted cancer cells may be accelerated if lymphatic flow is increased during surgery or radiotherapy.
Neuraxial anaesthesia such as spinal and epidural anaesthesia can temporarily block the sympathetic nervous system and therefore has the potential to reduce lymphatic flow during cancer surgery or radiotherapy. Recent experimental and observational studies suggest that the use of neuraxial anaesthesia may indeed be protective in preventing tumour recurrence when compared with general anaesthesia. 2 3 10 In a retrospective case -control study involving surgery for primary breast cancer, paravertebral blocks have been implicated in reducing the risk of subsequent disease progression and metastatic spread. 2 In another retrospective study of patients who underwent radical prostatectomy for prostatic cancer, the use of an epidural technique was associated with a 65% reduction in biochemical recurrence of prostate cancer. 3 We hypothesized that the use of neuraxial anaesthesia during brachytherapy, especially during the first session of treatment, may confer a potential protective effect on tumour recurrence and longterm survival in patients with cervical cancer.
Methods
This was a retrospective cohort study. After obtaining approval of the ethics committee of the Peter MacCallum Cancer Centre, the oncology and anaesthesia databases were linked to obtain data on patient characteristics, American Society of Anesthesiologists (ASA) status, tumour cell type (squamous cell or others), tumour staging according to the International Federation of Gynecologists and Obstetricians (FIGO), tumour volume, tumour invasion into the uterus, type of anaesthesia during all brachytherapy sessions, use of intraoperative and postoperative opioids, survival time, cause of death, and time to local or systemic recurrence of patients who had received bachytherapy between 1996 and 2003. Data collection was performed by two investigators who were blinded to the outcome data (J. Lynch and A. M. Power). Two investigators cross-checked the data using the recommended guidelines. 11 Data analysis was performed by two investigators (K.M.H. and S.K.-C.) independently who were not involved in the data collection process. Brachytherapy for cervical cancer involves cervical dilatation and insertion of brachytherapy applicators. High-dose fractionated radiotherapy is administered and the process requires about 60 min of anaesthesia and the procedure is usually repeated every 3-4 days. Subsequent sessions are usually shorter and involve less tissue trauma due to the creation of a channel and tumour shrinkage. Although not proven, tumour disruption and lymphatic spread is therefore likely to be maximal during the first session of brachytherapy. We hypothesized that the type of anaesthesia used during the first brachytherapy may have the maximal effect on tumour dissemination. As such, we have classified our patients into those who received neuraxial anaesthesia or general anaesthesia according to the type of anaesthesia used during their first session of brachytherapy. Patients who received spinal or epidural anaesthesia were classified as having neuraxial anaesthesia. The outcomes of this study included the survival time to either local or systemic recurrence and also long-term mortality due to tumour recurrence or all-cause mortality. Apart from assessing the outcomes for the whole cohort, a restricted analysis on patients who had an early-stage cancer (FIGO 1b -2b) (n¼96) was also conducted.
Sensitivity analyses included using the proportion of all brachytherapy sessions under neuraxial anaesthesia or a weighted proportion of brachytherapy under neuraxial anaesthesia (first session accounted for 50% of the total weighting) as an additional predictor during the multivariate analyses, and also using a primary site (i.e. cervix), pelvic lymph node, intra-abdominal recurrence as an alternative outcome. An additional five patients who received caudal anaesthesia, which usually did not induce significant sympathetic block, were also included in the group of patients who received general anaesthesia in a sensitivity analysis.
Categorical outcomes and outcomes with skewed distributions were compared by x 2 and Mann -Whitney tests, respectively. Cox proportional hazards regression was used to model the effect of neuraxial anaesthesia on time to recurrence and mortality. All known predictors of cervical cancer recurrence and long-term mortality were included in the multivariate analyses, and no predictor was removed during the modelling process. All statistical tests were twotailed, performed by SPSS (version 13.0, 2005, IL, USA) and a P-value of ,0.05 was regarded as significant.
Results
A total of 63 and 69 consecutive patients received neuraxial and general anaesthesia during their first brachytherapy session were considered, respectively. The age, ASA status, FIGO cancer staging, invasion into the uterus, tumour volume, and tumour cell types were not significantly different between patients who received neuraxial and general anaesthesia during their first brachytherapy treatment ( Table 1) . As expected, intraoperatively and after operation, systemic opioids were used much more often in patients who received general anaesthesia than those who received neuraxial anaesthesia during their first brachytherapy treatment (100% vs 32%, respectively, P¼0.001) ( (Fig. 1) . These results remained unchanged when the analyses were restricted to patients who had early cervical cancer (FIGO 1b-2b) (Tables 2 and 3) . Tumour recurrence and mortality were only significantly associated with the tumour cell type, tumour volume, and FIGO tumour staging. 
Sensitivity analyses

Discussion
Our results showed that the use of neuraxial anaesthesia for brachytherapy for cervical cancer was not associated with a reduced risk of local or systemic recurrence and mortality. Table 1 Difference between patients who received neuraxial anaesthesia (NA) and general anaesthesia (GA) during their first definitive brachytherapy. ASA, American Society of Anesthesiologists; SD, standard deviation. *By Mann -Whitney test. FIGO, International Federation of Gynecologists and Obstetricians: 1b, tumour is still limited to the pelvic area; 2a, tumour has spread beyond the cervix to the upper part of the vagina; 2b, tumour has spread to the tissue next to the cervix; 3a, tumour has spread to the lower third of the vagina; 3b, tumour has spread to the pelvic wall and/or blocks the flow of urine from the kidneys to the bladder; 4a, tumour has spread to organs located near the cervix, such as the bladder or rectum; 4b, tumour has spread to parts of the body far from the cervix
Variables
Neuraxial anaesthesia (n563) General anaesthesia (n569) P-value Our results confirmed the usual predictors of recurrence and long-term survival for patients with cervical cancer including age, uterine invasion, tumour volume, 12 but we could not confirm the beneficial effects of neuraxial anaesthesia on risks of tumour recurrence and mortality. There are three possible reasons. Firstly, our sample size may still be underpowered to demonstrate a small benefit of neuraxial anaesthesia. Our study (n¼132) was slightly smaller than the study by Biki and colleagues (n¼225); 3 hence, our results were imprecise with wide CIs. The negative results may well be due to a type II error. Secondly, the therapeutic procedure used for our patients was different from the other studies. It is possible that neuraxial anaesthesia is only useful in reducing tumour recurrence when there is extensive tumour tissue manipulation and disruption during the cancer surgery, such as opened radical prostatectomy, 3 mastectomy, 2 or bowel surgery. 1 Thirdly, the dose and duration of neuraxial anaesthesia used during and after tumour manipulation or disruption may have a significant effect on the potential protective effect of neuraxial anaesthesia in preventing seeding of the tumour. A session of brachytherapy usually requires 45-60 min of anaesthesia time; it is a procedure that is much shorter than radical prostatectomy, mastectomy, or bowel surgery. 1 -3 As such, the dose and duration of neuraxial anaesthesia used for this short procedure may not be effective in affecting the lymphatic flow of the operative field and hence seeding of the tumour. Furthermore, it is possible that systemic anaesthetic agents, such as propofol and opioids, may adversely affect the immune function of the body and increase the risk of tumour metastasis. 4 10 Although neuraxial anaesthesia was effective in reducing the use of systemic opioids, more than 30% of our patients who were treated with neuraxial anaesthesia still needed systemic opioids in the perioperative period. This might have reduced any potential beneficial effects of neuraxial anaesthesia on risk of tumour recurrence in our patients. This study has some limitations. Although we had followed current guidelines to improve data accuracy, bias and residual confounding are still possible. We did not have detailed co-morbidity data on our patients. Evidence suggests that co-morbidity has a significant effect on longterm survival of hospitalized patients. 13 14 Although statistically insignificant, the group of patients who received neuraxial anaesthesia was slightly older than the patients who received general anaesthesia. It is possible that neuraxial anaesthesia may have been used in patients who were perceived to be at higher risk for having general anaesthesia because of their associated co-morbidity. The severity of co-morbidity is a potential confounder that may affect our results. Our sample size only had a power of 80% to demonstrate a difference of more than 10% in mortality. A large prospective randomized controlled study is, therefore, needed to assess whether the use of neuraxial anaesthesia is beneficial in reducing tumour recurrence and mortality after cancer surgery, and whether this potential benefit is only restricted to extensive surgical procedures. In summary, neuraxial anaesthesia during brachytherapy for patients with cervical cancer was not associated with a reduced risk of tumour recurrence or mortality when compared with general anaesthesia. Until definitive outcome data from adequately powered randomized controlled studies are available, the choice of regional or general anaesthesia for brachytherapy should depend on procedural requirements, and the patient's general medical condition and preferences instead of its potential long-term effects on tumour recurrence. 
